Xieqiao J. Yan

Key Laboratory Of Carcinogenesis And Translational Research
Beijing, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 95 publications

Breakthroughs in malignancy therapy: New advances and emerging trends in renal cell carcinoma.

Breakthroughs in malignancy therapy: New advances and emerging trends in renal cell carcinoma.

Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
Published: April 30, 2026

HER2 assessment in urothelial carcinoma: standardization challenges and the path forward.

HER2 assessment in urothelial carcinoma: standardization challenges and the path forward.

Journal: Cancer metastasis reviews
Published: April 21, 2026

Features of tumor microenvironment in HER2-positive urothelial carcinoma and its implications for immunotherapy resistance.

Features of tumor microenvironment in HER2-positive urothelial carcinoma and its implications for immunotherapy resistance.

Journal: BMC cancer
Published: April 11, 2026

Evaluation and analysis of renal injury in patients with advanced renal cell carcinoma receiving first-line benmelstobart plus anlotinib: results from the ETER100 study.

Evaluation and analysis of renal injury in patients with advanced renal cell carcinoma receiving first-line benmelstobart plus anlotinib: results from the ETER100 study.

Journal: BMC medicine
Published: January 20, 2026

Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical Trial.

Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical Trial.

Journal: JAMA oncology
Published: January 02, 2026

Toripalimab in patients with previously treated advanced upper tract urothelial carcinoma: a subgroup analysis of the phase II POLARIS-03 trial.

Toripalimab in patients with previously treated advanced upper tract urothelial carcinoma: a subgroup analysis of the phase II POLARIS-03 trial.

Journal: The oncologist
Published: October 07, 2025

Advances in antibody-drug conjugates for urothelial carcinoma treatment.

Advances in antibody-drug conjugates for urothelial carcinoma treatment.

Journal: Cancer biology & medicine
Published: September 23, 2025

A phase II peri-operative study of pembrolizumab plus lenvatinib for mucosal melanoma.

A phase II peri-operative study of pembrolizumab plus lenvatinib for mucosal melanoma.

Journal: Nature communications
Published: August 08, 2025

MARCO+ Tumor-Associated Macrophages Impede CD8+ T Cell Immunity to Facilitate Immunotherapy Resistance in Renal Cell Carcinoma.

MARCO+ Tumor-Associated Macrophages Impede CD8+ T Cell Immunity to Facilitate Immunotherapy Resistance in Renal Cell Carcinoma.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: July 31, 2025

Disitamab vedotin with or without PD-1 inhibitors in pretreated patients with locally advanced or metastatic urothelial carcinoma: Identifying patients who derive additional benefit from immune combination therapy.

Disitamab vedotin with or without PD-1 inhibitors in pretreated patients with locally advanced or metastatic urothelial carcinoma: Identifying patients who derive additional benefit from immune combination therapy.

Journal: Urologic oncology
Published: June 30, 2025

Disease burden and future trend predictions of age-related hearing loss in China and worldwide from 1990 to 2021

Disease burden and future trend predictions of age-related hearing loss in China and worldwide from 1990 to 2021

Journal: Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
Published: June 13, 2025

Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma.

Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma.

Journal: Cancer management and research
Published: February 05, 2025
Showing 1-12 of 95

Last Updated: 09/26/2026